Patient Assistance

Although PROVENGE has robust coverage with major commercial and public payers, Dendreon is committed to helping your patients who are eligible for treatment gain access to patient assistance. Patient Assistance Programs can help your patients in many ways. Dendreon has continued to enhance the Patient Assistance Programs available by introducing PROvide, a program specifically designed for patients who are covered by commercial insurance.

Government Programs Patients Insured Through Government Programs (e.g. Medicare)*

  • A reimbursement coordinator can refer your patients to an independent foundation that provides financial assistance for co-pays, co-insurance, and deductible costs
  • Eligibility is determined by the independent foundation

Commercial Health Plans Patients Insured Through Commercial Health Plans

  • Patients may be eligible to access PROvide, the PROVENGE commercial co-pay program that provides financial assistance for co-pays, co-insurance, and deductible costs
  • Eligibility is determined by Dendreon

Support for Patients Without Coverage Support for Patients Without Coverage for PROVENGE

  • For eligible patients who do not have coverage for PROVENGE, Dendreon provides drug free of cost
  • In the event an eligible patient's claim for coverage for PROVENGE is denied by his payer after all appeals, the cost of the drug may be covered by Dendreon's patient assistance program
  • Eligibility criteria is determined by Dendreon

Travel Cost Assistance Travel Cost Assistance*

  • If your patient needs financial assistance with treatment-related travel costs, a case manager can refer him to an independent foundation to determine if he is eligible for help with these costs*
  • The program covers travel costs and provides a reservation service to book travel for patients
  • Eligibility is determined by the individual foundation
  PROvide Dendreon Patient Uninsured Program
Coverage Patients with commercial insurance only—no government-funded programs or uninsured patients Patients who do not have coverage for PROVENGE or who are denied by the payor after all appeals
Patient Diagnosis Asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (advanced prostate cancer) Asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (advanced prostate cancer)
Residency US resident US resident
Age Over 18 years of age Over 18 years of age
Income $150,000 adjusted gross income or less $150,000 adjusted gross income or less

Looking for more information about coverage options for your patients? Explore more:

*Co-pay and travel assistance foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by individual foundations. Dendreon ON Call can assist patients by referring them to these independent organizations. Dendreon cannot guarantee that patients will be eligible for or receive assistance after referral. Dendreon does not have controlling or managerial influence on these independent organizations.

PROvide, the commercial co-pay card program, and the Uninsured Patient Program eligibility criteria can be changed or program can be discontinued at any time at the sole discretion of Dendreon.

Patients with government-funded insurance including Medicare, Medicare Part D, Medicaid, or TriCare are not eligible.

New eServices!

Dendreon ON Call is now online, providing fast, efficient, secure access to patient enrollment and information.

Register Now | Sign in

INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

Full Prescribing Information